283 related articles for article (PubMed ID: 10162943)
21. Now there are eleven, but so what?
Gilden D
GMHC Treat Issues; 1997; 11(4/5):1-3. PubMed ID: 11364371
[TBL] [Abstract][Full Text] [Related]
22. New versions of antiretroviral guidelines contain some important changes.
Murphy MJ
Fac Notes (New Orleans La); 1999; 11(4):1-3. PubMed ID: 11810843
[No Abstract] [Full Text] [Related]
23. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
24. FDA Committee recommends clearance for HIVID combination therapy.
AIDS Patient Care STDS; 1996 Jun; 10(3):186. PubMed ID: 11361630
[No Abstract] [Full Text] [Related]
25. [New therapy for AIDS: a double-edged sword].
Foreman M
Sidahora; 1996; ():38-9. PubMed ID: 11364382
[TBL] [Abstract][Full Text] [Related]
26. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
Forsythe SS
AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
[TBL] [Abstract][Full Text] [Related]
27. Role of viral load blips, drug boosting, and therapeutic holidays in HIV patient management.
Bean P
Am Clin Lab; 2001 Sep; 20(8):11-3. PubMed ID: 11586932
[No Abstract] [Full Text] [Related]
28. Patient adherence, not viral load now most important in HIV therapy.
Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
[No Abstract] [Full Text] [Related]
29. Simply stated...on your mark, get set, go.
Res Initiat Treat Action; 1998 Jul; 4(4):15. PubMed ID: 11365644
[TBL] [Abstract][Full Text] [Related]
30. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
31. Undetectable HIV levels after triple therapy with indinavir.
AIDS Patient Care STDS; 1997 Jun; 11(3):193-4. PubMed ID: 11361795
[No Abstract] [Full Text] [Related]
32. Long-term virological outcome in patients infected with multi-nucleoside analogue-resistant HIV-1.
Clevenbergh P; Kirstetter M; Liotier JY; Dupon M; Philibert P; Jacomet C; Cua E; Montagne N; Schmit JC; Dellamonica P
Antivir Ther; 2002 Dec; 7(4):305-8. PubMed ID: 12553486
[TBL] [Abstract][Full Text] [Related]
33. HIV/AIDS treatment guidelines released.
Randall P
NIAID AIDS Agenda; 1997 Aug; ():1-2, 12. PubMed ID: 11364605
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
35. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
36. Current clinical treatments of AIDS.
Murphy EM; Jimenez HR; Smith SM
Adv Pharmacol; 2008; 56():27-73. PubMed ID: 18086408
[No Abstract] [Full Text] [Related]
37. Simplifying drug regimens.
HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
[TBL] [Abstract][Full Text] [Related]
38. [Seropositivity. Antiretrovirus treatments].
Tubiana R
Soins; 1998; (622):19-23. PubMed ID: 9574066
[No Abstract] [Full Text] [Related]
39. Protease inhibitors: opium of the masses?
Martinez LJ
Res Initiat Treat Action; 2000 Sep; 6(3):7-11. PubMed ID: 11708167
[No Abstract] [Full Text] [Related]
40. Drug combination shows benefits for AIDS patients with history of taking AZT.
AIDS Patient Care STDS; 1996 Jun; 10(3):185-6. PubMed ID: 11361628
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
